Comprehensive Characterization of Intraductal Oncocytic Papillary Neoplasm of the Pancreas: A Systematic and Critical Review.

Autor:	Paolino G; Section of Pathology, Department of Diagnostics and Public Health, University of Verona, Verona, Italy; Pathology Unit, Azienda Socio Sanitaria Territoriale Spedali Civili Di Brescia, Brescia, Italy., Basturk O; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York., Esposito I; Institute of Pathology, University Hospital of Duesseldorf, Duesseldorf, Germany., Hong SM; Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea., Brosens LA; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands., Tarcan Z; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York., Wood LD; Department of Pathology, Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland., Gkountakos A; Section of Pathology, Department of Diagnostics and Public Health, University of Verona, Verona, Italy., Omori Y; Section of Pathology, Department of Diagnostics and Public Health, University of Verona, Verona, Italy; Department of Investigative Pathology, Tohoku University Graduate School of Medicine, Sendai, Japan., Mattiolo P; Section of Pathology, Department of Diagnostics and Public Health, University of Verona, Verona, Italy., Ciulla C; Section of Pathology, Department of Diagnostics and Public Health, University of Verona, Verona, Italy., Marchegiani G; Department of Surgical, Oncological and Gastroenterological Sciences, University of Padua, Padua, Italy., Pea A; Department of Surgery, The Pancreas Institute, University and Hospital Trust of Verona, Verona, Italy., Bevere M; ARC-Net Research Center, University of Verona, Verona, Italy., De Robertis R; Section of Radiology, Department of Diagnostics and Public Health, University and Hospital Trust of Verona, Verona, Italy., D'Onofrio M; Section of Radiology, Department of Diagnostics and Public Health, University and Hospital Trust of Verona, Verona, Italy., Salvia R; Department of Surgery, The Pancreas Institute, University and Hospital Trust of Verona, Verona, Italy., Cheng L; Department of Pathology and Laboratory Medicine, The Warren Albert Medical School of Brown University, Lifespan Academic Medical Center, and the Legorreta Cancer Center at Brown University, Providence, Rhode Island., Furukawa T; Department of Investigative Pathology, Tohoku University Graduate School of Medicine, Sendai, Japan., Scarpa A; Section of Pathology, Department of Diagnostics and Public Health, University of Verona, Verona, Italy; ARC-Net Research Center, University of Verona, Verona, Italy., Adsay V; Department of Pathology, Koç University Hospital and Koç University Research Center for Translational Medicine, Istanbul, Turkey., Luchini C; Section of Pathology, Department of Diagnostics and Public Health, University of Verona, Verona, Italy; ARC-Net Research Center, University of Verona, Verona, Italy. Electronic address: claudio.luchini@univr.it.
Jazyk:	angličtina
Zdroj:	Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc [Mod Pathol] 2024 Sep; Vol. 37 (9), pp. 100554. Date of Electronic Publication: 2024 Jun 29.
DOI:	10.1016/j.modpat.2024.100554
Abstrakt:	Intraductal oncocytic papillary neoplasm (IOPN) of the pancreas is a recently recognized pancreatic tumor. Here, we aimed to determine its most essential features with the systematic review tool. PubMed, Scopus, and Embase were searched for studies reporting data on pancreatic IOPN. The clinicopathologic, immunohistochemical, and molecular data were extracted and summarized. Then, a comparative analysis of the molecular alterations of IOPN with those of pancreatic ductal adenocarcinoma and intraductal papillary mucinous neoplasm from reference cohorts (including The Cancer Genome Atlas) was conducted. The key findings from 414 IOPNs were as follows: 1) The male-to-female ratio was 1.5:1. Pancreatic head was the most common site (131/237; 55.3%), but a diffuse tumor extension involving more than one pancreatic segment was described in about 1 out of 5 cases (49/237; 20.6%). The mean size was 45.5 mm. An associated invasive carcinoma was present in 50% of cases (168/336). In those cases, most tumors were pT1 or pT2 and pN0 (>80%), and vascular invasion was uncommon (20.6%). Regarding survival, more than 90% of patients were alive after surgical resection. 2) Immunohistochemical and molecular features were as follows. The most commonly expressed mucins were MUC5AC (110/112; 98.2%) and MUC6 (78/84; 92.8%). Compared with pancreatic ductal adenocarcinoma and intraductal papillary mucinous neoplasm, the classic pancreatic drivers KRAS, TP53, CDKN2A, SMAD4, and GNAS were less altered in IOPN (P < .01). Moreover, fusions involving PRKACA or PRKACB gene were detected in all of the 68 cases examined, with PRKACB::ATP1B1 being the most common (27/68 cases; 39.7%). These genomic events emerged as an entity-defining molecular alteration of IOPN (P < .01). Thus, such fusions represent a promising biomarker for diagnostic purposes. Recent evidence also suggests their role in influencing the acquisition of oncocytic morphology. IOPN is a distinct pancreatic neoplasm with specific clinicopathologic and molecular features. Considering the clinical or prognostic implications, its recognition is essential for pathologists and, ultimately, patients' management. (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu